Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Sells Back Frova Rights; Vernalis Plans Menstrual Migraine Filing In 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Vernalis is seeking a new U.S. marketing partner for the triptan. Elan will use proceeds from the $55 mil. deal toward the Antegren launch.

You may also be interested in...



Endo To Boost Sales Force Following Frova In-Licensing Deal With Vernalis

The company will add about 70-80 reps to its existing sales force base of 230; detailing for the triptan will target specialty care physicians. Endo will make a $40 mil. milestone payment to Vernalis upon FDA approval for a menstrually associated migraine indication.

Endo To Boost Sales Force Following Frova In-Licensing Deal With Vernalis

The company will add about 70-80 reps to its existing sales force base of 230; detailing for the triptan will target specialty care physicians. Endo will make a $40 mil. milestone payment to Vernalis upon FDA approval for a menstrually associated migraine indication.

Eisai Acquires Elan's Zonegran; Will Detail With Aricept

Elan will receive a $130 mil. upfront payment and up to $110 mil. in milestone payments. Eisai does not plan to seek a co-promotion partner for the epilepsy agent.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel